Connect with Ross:
About the Guest:
Founder and CEO of CRISPR QC
Meet Ross Bundy, the co-founder and CEO of CRISPR QC. Having founded and successfully exited another venture, Cardea Bio, he’s a seasoned biotech entrepreneur with over a decade of experience in the field. This brings a strategic edge to CRISPR QC, where he leads with a passion for revolutionizing genetic medicine. Committed to making gene therapies safer, more accessible, and effective, Ross’s leadership is marked with a purpose-driven approach.
About the Episode:
For episode 83 of Entrepreneur Rx, John welcomes Ross Bundy, CEO of CRISPR QC. CRISPR QC is a biotechnology company aimed to equip scientists and researchers with data to improve their CRISPR assay design by using its sensor technology to analyze gene editing processes.
Ross starts off the episode by discussing his background in gene therapy and his experience founding Cardea Bio. He also talks about the challenges of introducing new ideas in a field dominated by experts and the importance of regulatory guidance. He goes on to explain more about how Cardea Bio and CRISPR QC are related, ethical issues in the field, challenges gene editing faces and his excitement of where CRISPR QC is headed.
He concludes the podcast by emphasizing the importance of building a strong team and finding people’s strengths to create a successful startup.He also shares his advice for those considering starting their own startup: build a support network, learn how to translate their expertise into value, and take responsibility for supporting and leading others.
Entrepreneur Rx Episode 83:
About CRISPR QC:
CRISPR QC stands as a cutting-edge leader in the field of genetic medicine. Headquartered in life science hub of San Diego, our pioneering work is driven by a commitment to bring fulfill the promise of CRISPR technologies. Our CRISPR Analytics Platform empowers researchers and biotechnology companies around the world with previously inaccessible data around editing activity. With a focus on optimizing CRISPR-Cas function, we provide invaluable insights, accelerating the development of revolutionary therapies and agricultural advancements. Join us in reshaping the landscape of genetic medicine at CRISPRQC.com
- Unlock new possibilities in gene editing by understanding the importance of diverse backgrounds and perspectives in driving innovation.
- Understand how networking can be a game-changer for gene editing entrepreneurs, opening doors to collaborations, funding, and career opportunities.
- Discover the power of perseverance and taking calculated risks in the field of gene editing, as it can lead to breakthroughs and advancements.
- Explore how you can learn to take prior skills and use them for entrepreneurship.
- Learn Ross’ biggest tip for entrepreneurship and what lies ahead for the future of CRISPR QC.
Follow Ross Bundy on LinkedIn to get the most up to date information on Ross’ journey.
- Learn about Ross and Kiana’s journey to founding CRISPR QC.
Follow CRISPR QC on LinkedIn to get the latest insights on what they are doing.
- Book a pilot study with CRISPR QC.
Check out CRISPR QC’s open opportunities on their website.
Read CRISPR QC’s case studies to better understand their potential.
Work with CRISPR QC by contacting them today.
Listen to this recent interview: Makers Bar Interview with Ross Bundy, CEO of CRISPR QC
00:00:05 – Introduction
Introducing the podcast and the guest, Ross Bundy, who has a unique background in Chinese history and has ventured into entrepreneurship with multiple startups.
00:00:35 – Ross’s Background and Entrepreneurial Journey
Ross shares his diverse background, including working in finance, manufacturing, and consumer packaged goods. He explains how he transitioned into venture capital and entrepreneurship, eventually co-founding Cardea Bio in 2013.
00:03:13 – Merging Skill Sets and Building Connections
Ross discusses how he leveraged his different skill sets from various industries and formed connections with experts in their fields. This approach allowed him to merge different skill sets and build something new.
00:05:17 – Leadership as an Empathic Field
Ross emphasizes that leadership is not a technical field but requires empathy and the ability to understand and leverage people’s strengths. He discusses how he takes on different responsibilities as an entrepreneur and hires experts as the company grows.
00:06:23 – Unusual Skill Set and Ability to Bring People Together
Ross acknowledges that his skill set is unusual but valuable. He shares how being an outsider in various groups has allowed him to adapt to different environments and bring people with different expertise together for success.
00:11:39 – The Power of Graphene in Life Science
Ross explains how graphene technology enables accessible and relevant biochemical and genetic testing by eliminating the need for complex chemical processes. This breakthrough allows for a more holistic approach to life science research and breaks down artificial silos between different verticals in the field.
00:13:18 – A Supply Chain Model for Graphene Production
Ross shares their unique approach to graphene production by building a supply chain instead of a traditional foundry. By leveraging existing skills and processes in the industry, they were able to integrate graphene into the silicon industry and scale production at a low cost.
00:15:30 – Transitioning to a Chip Company
Ross explains how he transitioned the company into a chip producer, partnering with companies in different markets to bring their technology to those industries. He compares his model to “intel inside” or “snapdragon” in the biology and biochemistry field.
00:16:59 – The Significance of CRISPR QC and Gene Editing
Ross provides an overview of CRISPR QC, describing it as a derived value with the potential to change the DNA of cells and create new organisms and opportunities. He highlights various applications such as genetic disease therapies, cancer treatment, and virus removal from DNA.
00:20:43 – Ethical Concerns
John and Ross then discuss the ethical concerns surrounding gene editing, citing the case of a Chinese scientist who faced legal consequences for gene
00:24:04 – The Fallibility of Scientists
Scientists, no matter how skilled, can make mistakes that have real consequences. The need for thorough risk assessment and consideration of potential factors is crucial to ensure the safety and acceptance of scientific advancements.
00:24:32 – Reluctance Towards CRISPR Therapy
Even scientists can have reservations about CRISPR therapy, as seen in the case of a couple who opted for a more invasive bone marrow transplant for their sickle cell-stricken children. The power and potential of scientific advancements must be balanced with caution and thorough understanding.
00:25:46 – Challenges of Gene Editing
Gene editing for single gene disorders like sickle cell can be relatively straightforward, but multiplex editing (targeting multiple genes simultaneously) is more difficult. Companies are making progress, but challenges and risks remain in editing diseases like HIV and cancer.
00:27:50 – Risks and Rewards
Gene editing strategies for cancer focus on tumor removal and improving chemotherapy success rates. While there are risks involved, the potential benefits for patients in late-stage cancer are significant. Some companies are taking risks to keep the promise of gene editing alive and make progress in the field.
00:28:29 – CRISPR QC’s Impact
CRISPR QC offers a unique measurement technique that allows for the quantification and control of gene editing outcomes. By understanding the variables and processes involved, researchers can move towards intentional and reproducible results.
00:35:49 – Challenging Established Ideas and Careers
Ross discusses how innovative ideas challenge established careers in the field. He has found more success with individuals who are open to new ideas and ways of thinking. Some leaders in the field feel challenged by CRISPR QC’s offerings.
00:37:03 – FDA’s Influence on Clinical Trials
The FDA’s lack of regulatory and safety guidance in the field slows down clinical trials. Currently, speed to clinical trials is more important to the FDA than accuracy. Smaller companies are more receptive to new ideas because they can bypass the challenges faced by larger companies.
00:38:12 – Resistance to New Ideas
Ross reflects on how some scientists and physicians are resistant to new ideas and technologies. Ross and John mention the example of Theranos, where many initially dismissed the technology but later realized its flaws. It’s important to have strong convictions but be open to objective data.
00:41:20 – Learning from Elon Musk
John and Ross discuss their admiration for Elon Musk’s ability to challenge the status quo and make a significant impact. However, they acknowledge that they couldn’t build a company like he does, but they appreciate the change he brings to the world.
00:47:05 – Introduction and Contact Information
Ross shares where listeners can find more information about him and encourages people to message him on LinkedIn (he usually always responds)
00:47:20 – Looking Forward to Working Together
Ross expresses excitement about working with John for the next couple of years and anticipates a great experience.